Yes , my blurry eyed morning self meant to say.
Potency assay approval will lead to manufacturing at scale.
That manufacturing at scale creates a valuation.
That valuation may be used in calculations of a takeover offer.
I expect Novartis will swallow Rem-L whole, if not all of Mesoblast.
Reg
Ann: CEO Presentation to 2021 Annual General Meeting, page-55
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.080(8.42%) |
Mkt cap ! $1.124B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | $1.03 | 95.0¢ | $31.48M | 30.73M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 72752 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 895049 | 6 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |